Feier Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feier Ding has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Nakamoto
Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan
2 shared publications - Hideyuki Fukui
Department of Radiology, Kindai University Faculty of Medicine, Sakai, Japan
2 shared publications - Noriyuki Tomiyama
Department of Radiology, Osaka University Graduate School of Medicine, Suita, Japan
2 shared publications - Toru Honda
Department of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan
2 shared publications - Eriko Yoshidome
Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan
1 shared publication - Gongzheng Wang
Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (4) , e70366
Intermuscular Adipose Tissue as a Multimodality Quantitative Imaging Biomarker: Evidence Across Metabolic, Cardiovascular and Oncologic Diseases
Intermuscular adipose tissue (IMAT) refers to adipose tissue located between muscle groups or beneath the muscle fascia, and its accumulation is closely linked to impaired muscle quality, reduced contractile function, and adverse metabolic profiles, establishing it as a core component of myosteatosis. Unlike subcutaneous and visceral adipose tissue, which reside outside the muscle architecture, IMAT expands within the muscle environment, where local metabolic and mechanical interactions may affect muscle integrity and performance. Elevated IMAT has been associated with diminished strength, impaired mobility, frailty, insulin resistance, and adverse cardiometabolic profiles, underscoring its clinical relevance beyond a passive fat depot. However, IMAT evidence remains dispersed across imaging techniques, anatomical regions, and disease‐specific literatures, limiting a unified understanding of its clinical utility. This review synthesizes current evidence on IMAT biology, imaging‐based quantification, disease‐specific distribution and clinical implications, with emphasis on its value as a risk‐stratification biomarker. Recent advances in medical imaging, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET), have enabled noninvasive and reproducible IMAT quantification. These modalities provide complementary measures of muscle fat infiltration, including CT‐derived area, volume and attenuation; MRI‐based segmentation and proton density fat fraction; ultrasound echo intensity; and PET‐derived metabolic activity. Deep learning–based segmentation methods have improved large‐scale IMAT quantification and reproducibility across anatomical regions. Mechanistically, IMAT is associated with chronic low‐grade inflammation and impaired glucose homeostasis, promoting progressive fat infiltration and muscle degeneration. Human studies indicate that IMAT exhibits an inflammatory secretory profile linked to insulin resistance and metabolic dysfunction. Quantitative imaging shows anatomically heterogeneous IMAT distribution, with frequent involvement of the lower extremities, paraspinal muscles and trunk. Across disease settings, IMAT appears to provide complementary information beyond muscle mass alone by capturing muscle quality and systemic vulnerability. Evidence is strongest in oncology, where elevated IMAT or IMAT‐based ratios have repeatedly been associated with poorer survival, recurrence, treatment toxicity, and reduced treatment tolerance. In metabolic and musculoskeletal disorders, IMAT is consistently related to insulin resistance, reduced strength, impaired mobility, and frailty, whereas cardiovascular evidence suggests prognostic relevance but remains less standardized and more heterogeneous. Clinically, IMAT imaging may help identify patients whose preserved muscle size or body mass index masks poor muscle quality, thereby refining prognostic assessment, perioperative risk evaluation, and selection for nutritional, exercise, metabolic, or treatment strategies. Future efforts should focus on standardized acquisition, automated segmentation, harmonized thresholds, and prospective validation to support integration of IMAT metrics into clinical decision‐making.
- 17 August 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (4) , e70366
Open AccessIntermuscular Adipose Tissue as a Multimodality Quantitative Imaging Biomarker: Evidence Across Metabolic, Cardiovascular and Oncologic Diseases
Intermuscular adipose tissue (IMAT) refers to adipose tissue located between muscle groups or beneath the muscle fascia, and its accumulation is closely linked to impaired muscle quality, reduced contractile function, and adverse metabolic profiles, establishing it as a core component of myosteatosis. Unlike subcutaneous and visceral adipose tissue, which reside outside the muscle architecture, IMAT expands within the muscle environment, where local metabolic and mechanical interactions may affect muscle integrity and performance. Elevated IMAT has been associated with diminished strength, impaired mobility, frailty, insulin resistance, and adverse cardiometabolic profiles, underscoring its clinical relevance beyond a passive fat depot. However, IMAT evidence remains dispersed across imaging techniques, anatomical regions, and disease‐specific literatures, limiting a unified understanding of its clinical utility. This review synthesizes current evidence on IMAT biology, imaging‐based quantification, disease‐specific distribution and clinical implications, with emphasis on its value as a risk‐stratification biomarker. Recent advances in medical imaging, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET), have enabled noninvasive and reproducible IMAT quantification. These modalities provide complementary measures of muscle fat infiltration, including CT‐derived area, volume and attenuation; MRI‐based segmentation and proton density fat fraction; ultrasound echo intensity; and PET‐derived metabolic activity. Deep learning–based segmentation methods have improved large‐scale IMAT quantification and reproducibility across anatomical regions. Mechanistically, IMAT is associated with chronic low‐grade inflammation and impaired glucose homeostasis, promoting progressive fat infiltration and muscle degeneration. Human studies indicate that IMAT exhibits an inflammatory secretory profile linked to insulin resistance and metabolic dysfunction. Quantitative imaging shows anatomically heterogeneous IMAT distribution, with frequent involvement of the lower extremities, paraspinal muscles and trunk. Across disease settings, IMAT appears to provide complementary information beyond muscle mass alone by capturing muscle quality and systemic vulnerability. Evidence is strongest in oncology, where elevated IMAT or IMAT‐based ratios have repeatedly been associated with poorer survival, recurrence, treatment toxicity, and reduced treatment tolerance. In metabolic and musculoskeletal disorders, IMAT is consistently related to insulin resistance, reduced strength, impaired mobility, and frailty, whereas cardiovascular evidence suggests prognostic relevance but remains less standardized and more heterogeneous. Clinically, IMAT imaging may help identify patients whose preserved muscle size or body mass index masks poor muscle quality, thereby refining prognostic assessment, perioperative risk evaluation, and selection for nutritional, exercise, metabolic, or treatment strategies. Future efforts should focus on standardized acquisition, automated segmentation, harmonized thresholds, and prospective validation to support integration of IMAT metrics into clinical decision‐making.
- 1 January 2026
- Published by Japanese Society for Magnetic Resonance in Medicine in Magnetic Resonance in Medical Sciences
- Vol. 25 (3)
MR Imaging of the Upper Urinary Tract: Techniques, Diagnostic Performance, and Imaging Biomarkers
MRI has become an increasingly important modality for evaluating the upper urinary tract. Although CT urography remains the standard imaging modality for assessing hematuria, MRI offers distinct advantages, including superior soft-tissue contrast, functional imaging capability, and a radiation-free evaluation, making it particularly valuable in certain clinical scenarios. This review provides a comprehensive overview of MRI of the upper urinary tract, with a focus on upper tract urothelial carcinoma (UTUC). Optimized MRI techniques, including T2-weighted imaging, MR urography, diffusion-weighted imaging (DWI), and contrast-enhanced T1-weighted imaging, are discussed with respect to their complementary roles in tumor detection, characterization, and local staging. MRI findings of UTUC are summarized, emphasizing the role of DWI in improving tumor detection and assessing renal parenchymal invasion. Beyond UTUC, the review addresses MRI features of non-UTUC neoplastic lesions, infectious and inflammatory diseases, and congenital anomalies of the upper urinary tract, underscoring the value of MRI in differential diagnosis. We discuss the potential role of MRI-derived imaging biomarkers, focusing on apparent diffusion coefficient measurements as noninvasive indicators of tumor aggressiveness and invasiveness. We also introduce emerging radiomics approaches as promising, albeit investigational, tools. As technical innovations continue and clinical evidence grows, the role of MRI in the personalized evaluation and management of upper urinary tract diseases is expected to expand.
- 1 January 2026
- Published by Japanese Society for Magnetic Resonance in Medicine in Magnetic Resonance in Medical Sciences
- Vol. 25 (3)
MR Imaging of the Upper Urinary Tract: Techniques, Diagnostic Performance, and Imaging Biomarkers
MRI has become an increasingly important modality for evaluating the upper urinary tract. Although CT urography remains the standard imaging modality for assessing hematuria, MRI offers distinct advantages, including superior soft-tissue contrast, functional imaging capability, and a radiation-free evaluation, making it particularly valuable in certain clinical scenarios. This review provides a comprehensive overview of MRI of the upper urinary tract, with a focus on upper tract urothelial carcinoma (UTUC). Optimized MRI techniques, including T2-weighted imaging, MR urography, diffusion-weighted imaging (DWI), and contrast-enhanced T1-weighted imaging, are discussed with respect to their complementary roles in tumor detection, characterization, and local staging. MRI findings of UTUC are summarized, emphasizing the role of DWI in improving tumor detection and assessing renal parenchymal invasion. Beyond UTUC, the review addresses MRI features of non-UTUC neoplastic lesions, infectious and inflammatory diseases, and congenital anomalies of the upper urinary tract, underscoring the value of MRI in differential diagnosis. We discuss the potential role of MRI-derived imaging biomarkers, focusing on apparent diffusion coefficient measurements as noninvasive indicators of tumor aggressiveness and invasiveness. We also introduce emerging radiomics approaches as promising, albeit investigational, tools. As technical innovations continue and clinical evidence grows, the role of MRI in the personalized evaluation and management of upper urinary tract diseases is expected to expand.